A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,300estimated
Sites
1
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-02 | actual | When the study began enrolling |
| Primary completion | 2026-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lower-risk Myelodysplastic Syndromes (TD LR-MDS)
Interventions
- Drug: Erythropoiesis-stimulating agents (ESAs)
- Biological: Luspatercept
- Drug: Lenalidomide
- Drug: Hypomethylating agents (HMAs)
- Biological: Reb blood cell transfusion
Primary outcomes
what the primary-completion date above is the date OFIncidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)
measured Up to 5-years
Prevalence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)
measured Up to 5-years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed